Expert Opinion on Investigational Drugs
Journal metrics
Annual Clarivate and SCImago indicators.
| Year | JCR | SJR | ||||
|---|---|---|---|---|---|---|
| IF | IF quartile | Rank (percentile) | SJR | SJR quartile | Rank (percentile) | |
| 2025 | 4.3 | Q2 | 73.6% | 1.199 | Q1 | 88.0% |
| 2024 | 4.1 | Q1 | 77.9% | 1.267 | Q1 | 89.5% |
| 2023 | 4.9 | Q1 | 87.5% | 1.414 | Q1 | 91.9% |
| 2022 | 6.1 | Q1 | 90.0% | 1.290 | Q1 | 91.0% |
| 2021 | 6.5 | Q1 | 88.2% | 1.177 | Q1 | 89.6% |
| 2020 | — | — | 1.410 | Q1 | 91.6% | |
| 2019 | — | — | 1.180 | Q1 | 88.9% | |
| 2018 | — | — | 1.076 | Q1 | 85.8% | |
Impact history
Annual SJR and Impact Factor trend.
SJRIF
Journal record
eISSN
1744-7658
ISSN
1354-3784
country
GBcoverage
1994-2026